Alivus Life Sciences Ltd · NSE:ALIVUS
Alivus Life Sciences — Glenmark Life Sciences — Q1 FY24 Earnings Presentation
20 slides from Alivus Life Sciences's earnings presentation, Jul 21, 2023
Slide 1: Exchange filing cover letter
July 21, 2023 To, To, Dy. General Manager The Manager – Listing, Department of Corporate Services, National Stock Exchange of India Ltd., BSE Ltd., Plot No. C/1, G Block, P. J. Towers, Dalal Street, Bandra Kurla Complex, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Ref: Scrip Code: 543322 Ref
Slide 2: Investor Presentation Q1 FY24
Investor Presentation Q1 FY24
Slide 3: Financial Performance Review
Financial Performance Review
Slide 4: Q1 FY24 Highlights
Q1 FY24 | Highlights “Our performance in the quarter was driven by Generic API and the CDMO businesses. Geographically, US, Europe, ROW and India markets spearheaded this Dr. Yasir Rawjee growth. Managing Director & We remain focused on our strategic priorities of building capacities as well as Chie
Slide 5: Q1 FY24 Performance
Q1 FY24 Performance Strong growth with stable margins PAT Revenue EBITDA EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) PAT Margin (In ₹) EBITDA Margin 18.1% 23.6% 22.2% 31.9% 33.7% 33.7% 23.4% 19.4% 6,213 1,464 11.94 30.2% 21.0% 2,093 5,407 5,093 4,899 28.1% 1,087 8.87 1,06
Slide 6: P&L Highlights Q1 FY24
P&L Highlights | Q1 FY24 Particulars (In ₹ Millions) Q1 FY24 Q4 FY23 QoQ Q1 FY23 YoY FY23 Revenue from Operations 5,785 6,213 -6.9% 4,899 18.1% 21,612 Gross Profit 3,304 3,409 -3.1% 2,610 26.6% 11,471 Gross Profit (%) 57.1% 54.9% 53.3% 53.1% Other Income 18 28 -34.7% 95 -80.5% 290 Employee Benefits
Slide 7: Strong Returns Indicators
Strong Returns Indicators ROICE Fixed Assets Turnover Working Capital Days 202 40% 176 171 165 36% 3.3 3.4 152 34% 35% 31% 2.9 2.9 98 102 111 99 89 152 136 120 116 126 FY20 FY21 FY22 FY23 Q1FY24 -48 -43 -53 FY20 FY21 FY22 FY23 Q1FY24 -67 -72 • ROICE is tracking at ~35% – Higher capital employed driv
Slide 8: Financial Performance Track Record
Financial Performance Track Record Robust growth and profitability indicators over the years Revenue EBITDA PAT EPS (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹ Milli o n s) (In ₹) EBITDA PAT EBITDA Margin PAT Margin 21.6% 31.0% 20.4% 19.7% 31.5% 31.4% CAGR 11.4% 29.7% 20.8% 18.6% 21,612 21,232 38.1
Slide 9: Business Performance Review
Business Performance Review
Slide 10: Segment Performance: Generic & CDMO business
Segment Performance | Generic & CDMO business Generic API CDMO (Rev enu e In ₹ Milli o n s) (Rev enu e In ₹ Milli o n s ) 5,299 568 5,042 4,799 309 279 243 4,533 4,448 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 • Generic API revenues in Q1FY24 increased by 13.3%
Slide 11: Segment Performance: GPL vs. External
Segment Performance | GPL vs. External External GPL GPL External (In ₹ Milli o n s) (In ₹ Milli o n s) % of Total Revenue % of Total Revenue 37.2% 33.9% 74.0% 62.8% 66.1% 34.0% 71.0% 29.0% 2,309 66.0% 3,755 3,904 26.0% 3,242 3,814 1,657 1,594 1,338 Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23 Q1 FY24 Q1 FY23 Q2
Slide 12: Market and Therapeutic Area Mix
Market and Therapeutic Area Mix Market Mix Therapeutic Area Mix 18% 19% 28% 25% 22% 29% 28% 39% 34% 39% 6% 8% Others 8% 6% 7% 5% 6% 4% Emerging 3% Pain Management 4% Markets 15% 14% 12% 18% Diabetes 15% 82% 81% 78% CNS 72% 75% Regulated CVS Markets 43% 42% 40% 36% 38% Q1 FY23 Q2 FY23 Q3 FY23 Q4 FY23
Slide 13: Company Overview
Company Overview LIFE SCIENCES
Slide 14: Global Footprint
Global Footprint • Filed 476 DMFs and CEPs across major markets; United States, Europe, Japan, Russia, Brazil, South Korea, Taiwan, Canada, China and Australia ROW 70+ 370+ 30+ 94 117 155 10+ 18 125+ 10+ 50+ 19 73 (Brazil) India – Mix of Regulated Number of Number of customers As of June 30, 2023 Re
Slide 15: R&D Capabilities
R&D Capabilities Cumulative Filing Status R&D Spend North (In ₹ Milli o n s) Therapy Europe Japan Brazil Australia ROW Total America R&D Spend CVS 37 31 4 20 10 30 132 As % to Sales CNS 35 22 8 13 1 14 93 Diabetes 9 4 8 12 33 3.0% 3.0% Pain Management 1 2 4 1 8 16 Others 73 35 6 28 7 53 202 2.6% 2.7
Slide 16: Quality-focused, compliant manufacturing & R&D infrastructure
Quality-focused, compliant manufacturing & R&D infrastructure Manufacturing Infrastructure R&D Infrastructure Annual Installed Capacity Last USFDA Mahape, Navi Mumbai Location Approvals (Jun-23) Inspection Date R&D for new product development and complex USFDA, MHRA (UK), FIMEA (Finland), molecule
Slide 17: Strategy Going Forward
Strategy Going Forward / LIFE SCIENCES
Slide 18: Strategic Growth Levers
Strategic Growth Levers 1 Gx API Business New product launches Geographical expansion Focus on new markets becoming more regulated New Growth levers 2 Pursue 2nd source opportunities with top generic players Ramp up CDMO portfolio Expand into complex API platforms Iron compounds Onco
Slide 19: Future Capacity Expansion Plan
Future Capacity Expansion Plan Operational Expansion Type Division Location Status & Planned Capacity Timelines 208 KL (Under Construction) FY24 Brownfield API / Intermediate Ankleshwar Planned addition of 280KL-300KL FY25-FY26 Brownfield API Dahej Planned addition of 220KL-240KL FY24-FY26 CTE recei
Slide 20: Thank You
Thank You FOR FURTHER INFORMATION CONTACT Email: complianceofficer@glenmarklifesciences.com ERNST & YOUNG LLP – INVESTOR RELATIONS DIWAKAR PINGLE RAHUL THAKUR Email: Diwakar.Pingle@in.ey.com Email: rahul.thakur@in.ey.com CORPORATE OFFICE: REGISTERED OFFICE: T: 91 22 68297979 4th Floor, OIA House, 47
Glenmark Life Sciences — Q1 FY24 Earnings Presentation on 6ix